Selected Grants
Increasing the Quality and Efficiency of Clinical Trials (U18)
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2014 - 2029Stimulating Access to Research in Residency (StARR) - NHLBI
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028RECHARGE Hybrid: Revascularization of Underrepresented Groups with minimally-invasive CABG plus PCI
ResearchCo-Mentor · Awarded by Thoracic Surgery Foundation for Research and Education · 2025 - 2027UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2016 - 2026OCEANIC Site Budget
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2023 - 2025Postdoctoral Training in Cardiovascular Clinical Research
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2003 - 2025CSL112_STEMI
Clinical TrialPrincipal Investigator · Awarded by CSL Behring LLC · 2017 - 2024ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab
Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2018 - 2023Myocardial Ischemia and Transfusion (MINT) Steering Committee
ResearchPrincipal Investigator · Awarded by Rutgers, The State University of New Jersey · 2016 - 2023ClotChip
Clinical TrialPrincipal Investigator · Awarded by XaTek Inc. · 2020 - 2022Core Clinical Centers for the CTSN
ResearchCo Investigator · Awarded by National Institutes of Health · 2007 - 2018Genetics Myocardial Adverse Outcomes/Graft Failure-CABG (Gene-Magic)
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2004 - 2011External Relationships
- Curis
- Eli Lilly & Co.
- Novostia
- Theravance, Inc
- Veralox therapeutics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.